CB-183,315 Compositions and Related Methods
The present disclosure provides novel solid CB-183,315 formulations which have improved chemical stability. The chemical stability of the solid CB-183,315 is dependent on the process by which the composition is made. Solid preparations of CB-183,315 can be prepared by the following method: (a) forming an aqueous solution of CB-183,315 and at least one sugar that (e.g., sucrose, trehalose or dextran) at a pH of 2-7, preferably pH 6 and (b) converting the aqueous solution to the solid preparation of CB-183,315 (e.g., via lyophilization or spray drying).
1 . A solid CB-183,315 preparation comprising CB-183,315 and at least one sugar selected from sucrose, trehalose or dextran, wherein the solid preparation is obtained by
a. forming an aqueous solution of the CB-183,315 and the sugar; and
b. converting the aqueous solution of (a) to the solid preparation.
2 . The solid CB-183,315 preparation of claim 1 wherein the CB-183,315 to sugar in step (a) is present in a range of about at least 1:0.5 to about 1:2 by weight.
3 . The solid CB-183,315 preparation of claim 1 , wherein the aqueous solution of step (a) is converted to the solid preparation in step (b) by lyophilization, spray drying, fluid bed drying or spray layering.
4 . The solid CB-183,315 preparation of claim 1 , obtained by
a. forming an aqueous solution comprising CB-183,315 and a sugar selected from sucrose or trehalose, wherein the CB-183,315 to sugar is present in a range of about at least 1:0.5 to about 1:2 by weight, at a pH of about 2-7, and
b. converting the aqueous CB-183,315 of step (a) to the solid preparation.
5 . A method of manufacturing a solid CB-183,315 preparation comprising
a. forming an aqueous solution comprising CB-183,315 and a sugar selected from sucrose or trehalose wherein the CB-183,315 to sugar is present in a range of about at least 1:0.5 to about 1:2 by weight, at a pH of about 2-7, and
b. converting the aqueous CB-183,315 of step (a) to the solid preparation.
6 . A tablet, capsule, sachet or oral dosing form comprising a composition of any of claims 1 - 4 .
7 . The tablet, capsule, sachet or oral dosing form of claim 6 further comprising one or more pharmaceutically acceptable excipients, carriers or adjuvents.
8 . A solid CB-183,315 preparation comprising:
85 weight percent of lyophilized CB-183,315/sucrose, 3.5 weight percent microcrystalline cellulose, 5 weight percent Croscarmellose sodium, 6 weight percent Silicon Dioxide, and 0.5 weight percent Magnesium Stearate, wherein the lyophilized CB-183,315/sucrose is prepared by
i. forming an aqueous solution of the CB-183,315 and sucrose at a ratio of CB-183,315 to sucrose of about 1:1.1, at a pH of about 6; and
ii. lyophilizing the solution of step (i) to give a lyophilized CB-183,315/sucrose.
9 . A solid CB-183,315 preparation comprising:
71.4 weight percent of CB-183,315/Trehalose spray dried material, 11.5 weight percent Mannitol, 11.5 weight percent microcrystalline cellulose, 4 weight percent polyvinyl pyrrolidone, 1 weight percent Silicon Dioxide and 0.6 weight percent Magnesium Stearate, wherein the CB-183,315/Trehalose spray dried material is prepared by
i. forming an aqueous solution of the CB-183,315 and trehalose at a ratio of CB-183,315 to trehalose of about 1:1.1, a pH of about 6; and
ii. spray drying the solution of step (i) to give a spray dried CB-183,315/trehalose.
10 . A pharmaceutical composition comprising CB-183,315 and sucrose, wherein the solid preparation is obtained by a process comprising the steps of
a. forming an aqueous solution of the CB-183,315 and sucrose at a pH of about 2-6; and
b. converting the aqueous solution of (a) to a solid preparation; and
c. compounding the solid preparation as the pharmaceutical composition for oral delivery.
11 . A solid CB-183,315 preparation comprising:
81-85 weight percent of lyophilized CB-183,315/sucrose, 3.5-7 weight percent microcrystalline cellulose, 5 weight percent Croscarmellose sodium, 1-6 weight percent Silicon Dioxide, and 0.5-1 weight percent Magnesium Stearate, wherein the lyophilized CB-183,315/sucrose is prepared by
i. forming an aqueous solution of the CB-183,315 and sucrose at a ratio of CB-183,315 to sucrose of about 1:1.1, at a pH of about 6; and
ii. lyophilizing the solution of step (i) to give a lyophilized CB-183,315/sucrose.
12 . A solid CB-183,315 preparation comprising:
81-85 weight percent of spray dried CB-183,315/sucrose, 3.5-7 weight percent microcrystalline cellulose, 5 weight percent Croscarmellose sodium, 1-6 weight percent Silicon Dioxide, and 0.5-1 weight percent Magnesium Stearate, wherein the lyophilized CB-183,315/sucrose is prepared by
i. forming an aqueous solution of the CB-183,315 and sucrose at a ratio of CB-183,315 to sucrose of about 1:1.1, at a pH of about 6; and
ii. spray drying the solution of step (i) to give a spray dried CB-183,315/sucrose.
13 . The composition of claim 10 , wherein the aqueous solution having a pH of about 6 is converted to the solid preparation by lyophilization, and the solid preparation is combined with one or more excipients to form the pharmaceutical composition.